The use of molecular markers to predict for optimal cytoreduction in ovarian cancer

被引：0
|
作者：
Fuh, K. [1 ]
Kiet, T. [1 ]
Chen, L. [1 ]
Sherman, A. [1 ]
Kapp, D. [2 ]
Chan, J. [1 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
29
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature
    Beissel, Joy M.
    Kendrick, Michael L.
    Podratz, Karl C.
    Bakkum-Gamez, Jamie N.
    GYNECOLOGIC ONCOLOGY REPORTS, 2014, 10 : 25 - 27
  • [42] Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
    Dhiman, Pravesh
    Bapsy, P. P.
    Patil, C. N.
    Raghupathi, Renu
    SOUTH ASIAN JOURNAL OF CANCER, 2022, 11 (03) : 207 - 212
  • [43] Optimal cytoreduction in stage IV ovarian carcinoma -: In reply
    Bonnefoi, H
    Gore, ME
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 3004 - 3004
  • [44] MOLECULAR MARKERS OF BREAST AND OVARIAN-CANCER
    STEEL, CM
    DISEASE MARKERS, 1991, 9 (3-4) : 213 - 223
  • [45] Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer
    Di Donna, Mariano Catello
    Cucinella, Giuseppe
    Zaccaria, Giulia
    Lo Re, Giuseppe
    Crapanzano, Agata
    Salerno, Sergio
    Giallombardo, Vincenzo
    Sozzi, Giulio
    Fagotti, Anna
    Scambia, Giovanni
    Lagana, Antonio Simone
    Chiantera, Vito
    CANCERS, 2023, 15 (02)
  • [46] Poster Session Can PET-CT predict complete secondary cytoreduction in ovarian cancer?
    Baiocchi, G.
    Fernandes, M. O.
    Faloppa, C. C.
    Kumagai, L. Y.
    Costa, A. A. B. A.
    Badiglian-Filho, L.
    Mantoan, H.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 112 - 112
  • [47] Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?
    Saygili, U
    Guclu, S
    Uslu, T
    Erten, O
    Demir, N
    Onvural, A
    GYNECOLOGIC ONCOLOGY, 2002, 86 (01) : 57 - 61
  • [48] Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
    Coleman, Robert L.
    Spirtos, Nick M.
    Enserro, Danielle
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah K.
    Kim, Jae-Weon
    Park, Sang-Yoon
    Kim, Byoung-Gie
    Nam, Joo-Hyun
    Fujiwara, Keiichi
    Walker, Joan L.
    Casey, Ann C.
    Alvarez Secord, Angeles
    Rubin, Steve
    Chan, John K.
    DiSilvestro, Paul
    Davidson, Susan A.
    Cohn, David E.
    Tewari, Krishnansu S.
    Basen-Engquist, Karen
    Huang, Helen Q.
    Brady, Mark F.
    Mannel, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (20): : 1929 - 1939
  • [49] Tertiary cytoreduction in the setting of recurrent ovarian cancer
    Dogan, Nasuh Utku
    Schneider, Achim
    Chiantera, Vito
    Dogan, Selen
    Dursun, Polat
    ONCOLOGY LETTERS, 2013, 6 (03) : 642 - 647
  • [50] Secondary cytoreduction for patients with recurrent ovarian cancer
    Díaz-Montes T.P.
    Bristow R.E.
    Current Oncology Reports, 2005, 7 (6) : 451 - 458
12345